Patents by Inventor Adam LEVINSON

Adam LEVINSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250199397
    Abstract: A first location within a mask pattern of a semiconductor circuit layout is determined, based on a feature of the mask pattern that is within a threshold distance of a boundary in the mask pattern. The mask pattern is based on a first mask exposure and a second mask exposure that meet at the boundary. The first location defines where to place a first assistive feature that reduces a sensitivity to lithographic process variations of the feature of the mask pattern. A second location of the mask pattern is also determined. The second location defines where to place a second assistive feature that reduces stray light at the boundary during the first mask exposure and the second mask exposure. The mask pattern is then modified to place the first assistive feature in the first location and the second assistive feature in the second location.
    Type: Application
    Filed: December 14, 2023
    Publication date: June 19, 2025
    Inventors: Robert Michal Iwanow, Zachary Adam Levinson, Kevin Dean Lucas, James Erwin Burdorf
  • Patent number: 11900042
    Abstract: In some aspects, a mask pattern is accessed. The mask pattern is for use in a lithography process that prints a pattern on a wafer. The mask pattern is applied as input to a deterministic model of the lithography process to predict a characteristic of the printed pattern. The deterministic model is deterministic, but it accounts for local stochastic variations of the characteristic in the printed pattern.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: February 13, 2024
    Assignee: Synopsys, Inc.
    Inventors: Kevin Dean Lucas, Yudhishthir Prasad Kandel, Ulrich Welling, Ulrich Karl Klostermann, Zachary Adam Levinson
  • Publication number: 20230365584
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.
    Type: Application
    Filed: September 8, 2021
    Publication date: November 16, 2023
    Inventors: Xianhai HUANG, Sayan MONDAL, Phani GHANAKOTA, Nicholas BOYLES, Leah FRYE, Adam LEVINSON, Jeremy Robert GREENWOOD, Pieter BOS, Sathesh BHAT, Aleksey GERASYUTO, Haifeng TANG
  • Patent number: 11415897
    Abstract: Calibrating stochastic signals in compact modeling is provided by obtaining data of process variations in producing a resist mask; calibrating a continuous compact model of the resist mask based on the data; evaluating the continuous compact model against a stochastic compact model that is based on the data; choosing a functional description of an edge location distribution for the stochastic compact model; mapping image parameters from the evaluation to edge distribution parameters according to the functional description; determining an edge location range for the stochastic compact model based on scaled measurements from the image parameters; calibrating a threshold for the resist mask and updating parameters of the stochastic compact model to reduce a difference between the data and a modeled Line Edge Roughness (LER) value; and outputting the stochastic compact model.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 16, 2022
    Assignee: Synopsys, Inc.
    Inventors: Zachary Adam Levinson, Yudhishthir Prasad Kandel, Ulrich Welling
  • Publication number: 20220146945
    Abstract: In some aspects, a mask pattern is accessed. The mask pattern is for use in a lithography process that prints a pattern on a wafer. The mask pattern is applied as input to a deterministic model of the lithography process to predict a characteristic of the printed pattern. The deterministic model is deterministic, but it accounts for local stochastic variations of the characteristic in the printed pattern.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 12, 2022
    Inventors: Kevin Dean Lucas, Yudhishthir Prasad Kandel, Ulrich Welling, Ulrich Karl Klostermann, Zachary Adam Levinson
  • Publication number: 20210382394
    Abstract: Calibrating stochastic signals in compact modeling is provided by obtaining data of process variations in producing a resist mask; calibrating a continuous compact model of the resist mask based on the data; evaluating the continuous compact model against a stochastic compact model that is based on the data; choosing a functional description of an edge location distribution for the stochastic compact model; mapping image parameters from the evaluation to edge distribution parameters according to the functional description; determining an edge location range for the stochastic compact model based on scaled measurements from the image parameters; calibrating a threshold for the resist mask and updating parameters of the stochastic compact model to reduce a difference between the data and a modeled Line Edge Roughness (LER) value; and outputting the stochastic compact model.
    Type: Application
    Filed: June 4, 2021
    Publication date: December 9, 2021
    Inventors: Zachary Adam LEVINSON, Yudhishthir Prasad KANDEL, Ulrich WELLING
  • Patent number: 10184907
    Abstract: Disclosed are magnetic nanosensors or transducers that permit measurement of a physical parameter in an analyte via magnetic reasonance measurements, in particular of non-agglomerative assays. More particularly, in certain embodiments, the invention relates to designs of nanoparticle reagents and responsive polymer coated magnetic nanoparticles. Additionally provided are methods of use of nanoparticle reagents and responsive polymer coated magnetic nanoparticles for the detection of a stimulus or an analyte with NMR detectors.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 22, 2019
    Assignee: T2 Biosystems, Inc.
    Inventors: Thomas Jay Lowery, Jr., James Joseph Koziarz, Douglas Adam Levinson, David A. Berry, Tuan A. Elstrom, Sonia Kumar, Mark John Audeh
  • Publication number: 20160033494
    Abstract: Disclosed are magnetic nanosensors or transducers that permit measurement of a physical parameter in an analyte via magnetic reasonance measurements, in particular of non-agglomerative assays. More particularly, in certain embodiments, the invention relates to designs of nanoparticle reagents and responsive polymer coated magnetic nanoparticles. Additionally provided are methods of use of nanoparticle reagents and responsive polymer coated magnetic nanoparticles for the detection of a stimulus or an analyte with NMR detectors.
    Type: Application
    Filed: October 8, 2015
    Publication date: February 4, 2016
    Inventors: Thomas Jay LOWERY, JR., James Joseph KOZIARZ, Douglas Adam LEVINSON, David A. BERRY, Tuan A. ELSTROM, Sonia KUMAR, Mark John AUDEH
  • Publication number: 20120171204
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Application
    Filed: June 23, 2011
    Publication date: July 5, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Clare M. Lloyd, Sean A. McCarthy
  • Publication number: 20110123548
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Application
    Filed: March 23, 2010
    Publication date: May 26, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Clare M. Lloyd, Sean A. McCarthy
  • Publication number: 20090041752
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Application
    Filed: July 31, 2007
    Publication date: February 12, 2009
    Inventors: Douglas Adam Levinson, Clare M. Lloyd, Sean A. McCarthy
  • Patent number: 7172750
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: February 6, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • Publication number: 20030158399
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Application
    Filed: September 20, 2002
    Publication date: August 21, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • Patent number: 6562343
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: May 13, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • Publication number: 20030069196
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Application
    Filed: December 4, 2001
    Publication date: April 10, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Clare M. Lloyd, Sean A. McCarthy
  • Patent number: 6455685
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: September 24, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • Publication number: 20020115140
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS (“regulator of G-protein signalling”) gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Application
    Filed: June 4, 2001
    Publication date: August 22, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 6414117
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: July 2, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • Patent number: 6395872
    Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; 8 transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library corresp
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: May 28, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson
  • Patent number: 6391586
    Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; (c) transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library corre
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: May 21, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson